Company intelligence / Profile preview
Guilin Pharmaceutical
- Ownership
- Private
- Development stage
- Other
Overview
Guilin Pharmaceutical is a leading Chinese pharmaceutical company with global dominance in artemisinin-based antimalarial drugs. Its artesunate for injection was the first Chinese drug to receive WHO prequalification and has been widely used in malaria-endemic regions, contributing significantly to reductions in child malaria mortality. The company also produces a broad portfolio of generic pharmaceuticals and APIs, with several products passing China’s generics consistency evaluation.[3][6]
- Therapeutic areas
- CardiovascularInfectious Diseases
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Guilin Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guilin Pharmaceutical.